Corporate & Investor Presentation

Reconciliation of non-GAAP financial measures, cont'd The measure "non-GAAP net income" and "non-GAAP diluted earnings per share" are reconciled with GAAP net income and GAAP diluted earnings per share in the table below: (Unaudited; $ in thousands, except for per share amounts) Three Months Ended March 31, 2022 March 31, 2021 Nine Months Ended March 31, 2022 March 31, 2021 GAAP net income (loss) $ 179,012 $ Amortization of acquired intangibles-cost of sales, net of tax (A) 8,374 (78,481) $ 8,395 584,376 $ 279,405 25,373 26,136 Amortization of acquired intangibles-operating expenses, net of tax (A) 5,894 5,721 17,673 17,936 Reserve for disputed tax position (A) 254,776 4,111 254,776 Restructuring cost of sales, net of tax (A) 4,663 Restructuring operating expenses, net of tax (A) 7,730 (Gain) loss on equity investments (A) (8,476) Non-GAAP net income (A) $ 193,280 $ GAAP diluted shares outstanding 146,962 Anti-dilutive shares excluded from GAAP Non-GAAP diluted shares outstanding 146,962 GAAP diluted earnings (loss) per share Non-GAAP diluted earnings per share (A) $ SS 1.22 $ $ 1.32 $ 190,411 $ 145,513 858 146,371 (0.54) $ 1.30 $ 631,533 $ 582,170 147,034 146,394 147,034 146,394 4.30 3.97 $ $ 1.91 3.98 Note regarding non-GAAP reconciliations ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions, restructuring expenses and the (gain) loss on equity investments from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance. ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed's performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. 37 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed

View entire presentation